Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-40 (IL-40), encoded by the C17orf99 gene on chromosome 17q25.3, is a recently identified small secreted cytokine unique to mammals, primarily expressed in bone marrow, fetal liver, and activated B cells, with a pivotal role in the regulation of humoral immunity. IL-40 modulates B cell differentiation and maturation, stimulates IgA synthesis, and participates in maintaining B cell homeostasis, with important links to the composition of the gut microbiome and mammary gland function. It becomes upregulated in several inflammatory and autoimmune conditions, such as rheumatoid arthritis, where it correlates with disease activity and tissue remodeling. IL-40 is also implicated in B cell lymphoma biology and may play roles in mucosal immunity and antiviral responses. Structurally, it lacks homologs in other cytokine families ("orphan cytokine"), and its mechanisms of action and therapeutic potential remain under active investigation
Not directly targeted by known drugs; biological effects modulated via antibody-based therapies affecting B cells (e.g., rituximab); would act via cytokine-receptor interaction if a drug is developed
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-40 (IL-40).